6月5日，艾伯维公司盘中上涨3.09%，报223.85美元/股，成交额7.55亿美元。
消息面上，Rothschild&Co Redburn于6月4日将艾伯维目标价从265美元上调至284美元，维持买入评级。据FactSet数据，分析师对艾伯维平均评级为"超配"，平均目标价253.85美元。此外，近期公司迎来多项产品利好：其ADC疗法Pivekimab sunirine获美国FDA批准上市，用于治疗母细胞性浆细胞样树突细胞肿瘤，系全球首个获批的CD123 ADC；同时，Venclyxto获欧盟委员会批准扩大标签，新增与阿卡替尼布、伊布替尼联合用药方案，为慢性淋巴细胞白血病一线治疗提供无化疗固定疗程选择。多重利好共振推动股价走高。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.